Curevac’s patent involves an mRNA sequence for RSV infections, focusing on a pharmaceutical composition with a modified RSV-F protein. The composition aims to develop a vaccine for prophylaxis or treatment of RSV infections, utilizing a specific mRNA molecule formulation. GlobalData’s report on Curevac gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Curevac, Personalized cancer vaccines was a key innovation area identified from patents. Curevac's grant share as of April 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for rsv vaccine with modified fusion protein
A recently granted patent (Publication Number: US11965000B2) discloses a pharmaceutical composition comprising a mRNA molecule encoding a Respiratory Syncytial Virus fusion protein (RSV-F) with a deleted C-terminus (F-del), lacking specific amino acids. The mRNA molecule is formulated with a cationic lipid and includes a 5'-cap structure, 5' and 3' untranslated regions, a poly(A) sequence, and a stabilizing sequence from the alpha globin 3' UTR. Additionally, the composition may include a second mRNA encoding an antigen from a different virus. The pharmaceutical composition is designed for intramuscular injection and aims to stimulate an immune response to RSV by producing RSV neutralizing antibodies.
Furthermore, the patent also covers a method for stimulating an immune response to RSV in a subject by administering the pharmaceutical composition described above. The method involves intradermal or intramuscular injection of the composition, which includes a cationic component and a poly(A) sequence of specific length. By utilizing this method, an increased amount of RSV neutralizing antibodies can be generated compared to compositions encoding full-length RSV-F. The method emphasizes the importance of the specific mRNA structure, including the 5' cap structure, 3' UTR stabilizing sequence, and the inclusion of a transmembrane domain of native RSV-F, in enhancing the immune response against RSV.
To know more about GlobalData’s detailed insights on Curevac, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
